Olutasidenib
Catalog No: 20791
CAS Number: 1887014-12-1
Purity: 98%
Olutasidenib (FT-2102) is a potent mutant-selective IDH1 inhibitor. Olutasidenib (FT-2102) has excellent ADME/PK properties and reduces 2-hydroxyglutarate levels in a mIDH1 xenograft tumor model. Olutasidenib (FT-2102) has been selected as a candidate for clinical development in hematologic malignancies, solid tumors, and gliomas with mIDH1.
For research use only. We do not sell to patients.
Chemical Information
| Name | Olutasidenib |
|---|---|
| Iupac Chemical Name | (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| Synonyms | FT-2102 ; olutasidenib ; FT2102 ; FT 2102 |
| Molecular Formula | C18H15ClN4O2 |
| Molecular Weight | 354.79 |
| Smile | N#CC1=CC=C(N[C@H](C2=CC3=C(NC2=O)C=CC(Cl)=C3)C)C(N1C)=O |
| InChiKey | NEQYWYXGTJDAKR-JTQLQIEISA-N |
| InChi | InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1 |
| CAS Number | 1887014-12-1 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Brittle foam |
|---|---|
| Purity | 98% |
| Storage | 3 years -20ºCpowder 6 months-80ºCin solvent |
| Solubility | Soluble in DMSO to 20 mM |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping. |
| HS Code |
Coming soon.
| Targets | Mutant-selective IDH1 inhibitor |
|---|---|
| Mechanism | olutsidenib ( FT-2102 ) is a CNS-penetrant mIDH1 inhibitor that is currently undergoing clinical evaluation in several types of mIDH1-dependent cancers, including hematologic malignancies, solid tumors, and gliomas. |
| Cell study | |
| Animal study | |
| Clinical study | Olutasidenib is currently being evaluated in a registrational Phase 2 trial for relapsed/refractory (R/R) AML and an exploratory Phase 1 trial for glioma. |
Not available
Chemical Structure
